INDBInternet News Database 2.5 Updated just now · 292 sources Show or hide images Light or dark

ADC May Beat Conventional Chemotherapy in NSCLC

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage

Summary

A phase 3 trial evaluates an antibody-drug conjugate plus pembrolizumab vs chemotherapy plus pembrolizumab as first-line treatment for patients with PD-L1-negative advanced non-small cell lung cancer.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    ADC May Beat Conventional Chemotherapy in NSCLC

    A phase 3 trial evaluates an antibody-drug conjugate plus pembrolizumab vs chemotherapy plus pembrolizumab as first-line treatment for patients with PD-L1-negative advanced non-small cell lung cancer.

Comments

Comments need JavaScript.